Clinical Evidence

Prevenar 13^® offers proven, lasting protection against pneumococcal pneumonia¹

• In a large-scale efficacy trial, which included 84,496 subjects ≥65 years of age:
  Prevenar 13^® reduced the first episode incidence of vaccine-type community-acquired pneumococcal pneumonia by 46% vs. placebo (p<0.001; 49/42,240 vs. 90/42,256)¹
• The clinical trial results indicated Prevenar 13^® provided statistically significant reductions in hospital-confirmed cases of vaccine-type (VT) pneumococcal CAP and invasive pneumococcal disease (IPD) in adults aged ≥65 years¹
• Prevenar 13^® demonstrated lasting protection: efficacy of Prevenar 13^® vs. placebo persisted throughout the 4-year trial without evidence of waning (post-hoc analysis)¹
• Prevenar 13^® will only protect against Streptococcus pneumoniae serotypes included in the vaccine. Prevenar 13^® does not provide 100% protection against vaccine serotypes nor protect against nonvaccine serotypes.²

In Ireland when comparing Invasive Pneumococcal Disease in 2018 against 2008 there was; ³

• 100% decline in PCV 7 serotypes in those aged <5 years old³
• 80% decline in the additional 6 serotypes in PCV 13 in those ages <2 years due to the additional six serotypes covered by PCV13. ³

References

1. Bonten MJM, et al. Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults. N Engl J Med. 2015;372(12):1114-1125
2. Prevenar 13^® Summary of Product Characteristics. November 2020
3. HSE Health Protection Surveillance Centre. Streptococcus pneumoniae (invasive) in Ireland, 2018. Dublin: HSE HPSC; 2019. Available at: https://www.hpsc.ie/az/vaccinepreventable/pneumococcaldisease/publications/annualreportsoninvasivepneum ococcaldisease/Streptococcus%20pneumoniae%20invasive%20in%20Ireland%202018.pdf Last Accessed: February 2022